Braze beat Q2 estimates and raised guidance, but shares fall. Analysts remain bullish on AI tailwinds.
Braze beat Q2 ($227.2M, +26% YoY) and raised guidance but stock fell 19% as cRPO decelerated to 23.8% from 28.4%. BrazeAI growth (+136%) couldn't offset organic concerns; analysts maintain Overweight/Buy ratings, viewing valuations as a buying opportunity.
Shares of Braze Inc (NASDAQ:BRZE) tanked on Wednesday, despite the company reporting upbeat fiscal second-quarter results.
Here are some key analyst takeaways:
Stephens analyst Brett Huff maintained an Overweight rating, while raising the price target from $31 to $34.
Citizens JMP Securities analyst Patrick Walravens reiterated a Market Outperform rating and price target of $35.
BTIG analyst Nick Altmann reaffirmed a Buy rating and price target of $35.
Braze beat Q2 estimates and raised FY2027 guidance, but shares fell 13.7%; analysts lifted or maintained price targets.
Braze (BRZE) beats Q2 earnings and revenue estimates, but stock drops 18% on weak Q3 EPS guidance. Get the full breakdown.
Braze shares fell after reporting mixed Q1 results. Cantor Fitzgerald and DA Davidson analysts remain bullish on raised FY27…
Shares of Braze are climbing ahead of Q1 earnings report. Analyst expects organic growth acceleration and higher guidance.
TD Cowen analyst Derrick Wood reiterated a Buy rating on Braze yesterday and set a price target of $36.00. According to TipRanks,…
There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Workday (WDAY) and Braze (BRZE)…
